Abstract
Rituximab is an anti-CD20 monoclonal antibody often used in the treatment of rheumatoid arthritis (RA). Infusion reactions sometimes develop following rituximab administration. Delayed complications are rare. Acute coronary syndromes are listed as sideeffects of rituximab therapy. We report two cases of acute myocardial infarction following rituximab therapy for RA and review the literature regarding cardiac events in patients treated with rituximab. We would like to raise awareness of this possible complication in patients treated with rituximab.
Keywords: Rituximab, rheumatoid arthritis, cardiovascular disease, myocardial infarction.
Current Pharmaceutical Design
Title:Myocardial Infarction after Rituximab Treatment for Rheumatoid Arthritis: Is there a Link?
Volume: 20 Issue: 4
Author(s): Alper M. van Sijl, Wilfred van der Weele and Michael T. Nurmohamed
Affiliation:
Keywords: Rituximab, rheumatoid arthritis, cardiovascular disease, myocardial infarction.
Abstract: Rituximab is an anti-CD20 monoclonal antibody often used in the treatment of rheumatoid arthritis (RA). Infusion reactions sometimes develop following rituximab administration. Delayed complications are rare. Acute coronary syndromes are listed as sideeffects of rituximab therapy. We report two cases of acute myocardial infarction following rituximab therapy for RA and review the literature regarding cardiac events in patients treated with rituximab. We would like to raise awareness of this possible complication in patients treated with rituximab.
Export Options
About this article
Cite this article as:
Sijl M. van Alper, Weele van der Wilfred and Nurmohamed T. Michael, Myocardial Infarction after Rituximab Treatment for Rheumatoid Arthritis: Is there a Link?, Current Pharmaceutical Design 2014; 20 (4) . https://dx.doi.org/10.2174/13816128113199990386
DOI https://dx.doi.org/10.2174/13816128113199990386 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Low-Dose Methotrexate (LD-MTX) in Rheumatology Practice - A Most Widely Misunderstood Drug
Current Rheumatology Reviews Molecular Mechanisms of Drug Photodegradation and Photosensitization
Current Pharmaceutical Design Extracellular Tropomyosin: A Novel Common Pathway Target for Anti- Angiogenic Therapy
Current Cancer Drug Targets Immune Aging and Autoimmune Diseases in Children
Current Immunology Reviews (Discontinued) Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Folate Receptor Targeted Liposomes
Drug Design Reviews - Online (Discontinued) Design, Synthesis, Characterization and Bioactivity Evaluation of New Symmetric Disulfonamides and Dicarbamates of 4,4'-Oxydianiline
Anti-Infective Agents The Effect of TNFα-Inhibitors on Cardiovascular Events in Patients with Rheumatoid Arthritis: An Updated Systematic Review of the Literature
Current Rheumatology Reviews The Prevention of Preterm Labour - Corticotropin Releasing Hormone Type 1 Receptors as a Target for Drug Design and Development
Mini-Reviews in Medicinal Chemistry Treatment of Ankylosing Spondylitis with Biologic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Natural and Synthetic Inhibitors of Caspases: Targets for Novel Drugs
Current Drug Targets - CNS & Neurological Disorders Patent Selections
Recent Patents on Medical Imaging Combined Anticancer Therapies: An Overview of the Latest Applications
Anti-Cancer Agents in Medicinal Chemistry Anti-Inflammatory Iridoids of Botanical Origin
Current Medicinal Chemistry n-3 Polyunsaturated Fatty Acids and the Prevention of Colorectal Cancer: Molecular Mechanisms Involved
Current Medicinal Chemistry Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design The Contribution of γδ T Cells to the Pathogenesis of EAE and MS
Current Molecular Medicine Retinoids as Differentiating Agents in Oncology: A Network of Interactions with Intracellular Pathways as the Basis for Rational Therapeutic Combinations
Current Pharmaceutical Design Structure-Based Rationale for Interleukin 5 Receptor Antagonism
Current Pharmaceutical Design Multi-Target Profile of Oleocanthal, An Extra-Virgin Olive Oil Component
Current Bioactive Compounds